News

IRVINE, Calif., March 27, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter and year ended December 31, 2022 and provided a business update. 2022 and Recent Highlights “We made…

U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Belzupacap Sarotalocan (bel-sar) for the Treatment of Choroidal Metastasis, Bel-sar’s Second Ocular Oncology Indication to Receive this Designation Global Phase 3 Trial in Primary Choroidal Melanoma on Track to Begin Dosing in 1H 2023 BOSTON–(BUSINESS WIRE)–Mar. 15, 2023– Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company…

U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Belzupacap Sarotalocan (bel-sar) for the Treatment of Choroidal Metastasis, Bel-sar’s Second Ocular Oncology Indication to Receive this Designation Global Phase 3 Trial in Primary Choroidal Melanoma on Track to Begin Dosing in 1H 2023 BOSTON–(BUSINESS WIRE)–Mar. 15, 2023– Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company…

March 15, 2023 Download PDF EMERYVILLE, Calif., March 15, 2023 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, ‘4DMT’), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, today announced full year 2022 financial results and provided operational highlights. “We are proud to have validated 4DMT’s Therapeutic Vector…

Topline data from the STRIDE study expected in the fourth quarter of 2023 IRVINE, Calif., March 14, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company has achieved the target enrollment…

– LIVMARLI immediately available for prescribing for patients three months of age and older FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a reduction in age from one year to three months for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in…